Research | Open | Published:
Changes in the expression of MMP2, MMP9, and ColIV in stromal cells in oral squamous tongue cell carcinoma: relationships and prognostic implications
Journal of Experimental & Clinical Cancer Researchvolume 31, Article number: 90 (2012)
Type IV collagen (ColIV) is the most important scaffold for the basement membrane (BM) proteins, and plays an important role in regulating and limiting tumour invasion and metastasis.
Here, we observed the changes in morphology and distribution of type IV collagen (ColIV) in the basement membrane (BM) surrounding nests of carcinoma in 48 patients with oral tongue squamous cell (OTSCC). We examined the correlation between the expressions of ColIV, MMP-2 and MMP-9 and the prognosis of OTSCC patients. The intensity and patterns of expression were assessed immunohistochemically using anti-human mouse monoclonal MMP-2, MMP-9 and Col IV antibodies. Statistical analyses were performed to determine the prognostic correlations of ColIV, MMP-2, and MMP-9 levels.
MMP-2 and MMP-9 expressions in OTSCC were higher than those in normal oral mucosa and dysplastic oral mucosa group(MMP-2 iOD: 66.40 ± 24.20, 134.69 ± 37.08, and 357.79 ± 116.78; MMP-9 iOD: 88.05 ± 23.85, 307.13 ± 93.22, and 791.31 ± 260.52; in normal, dysplastic oral mucosa, and tumour tissues, respectively, P < 0.01); however, ColIV immunoreactivity was lower (ColIV iOD: 406.87 ± 62.95, 247.83 ± 42.30, and 151.92 ± 38.17 in normal, dysplastic oral mucosa, and tumour tissues, respectively, P < 0.01). High tumour and stromal MMP-2 and MMP-9 expression was significantly associated with positive lymph node status. Col IV expression was associated with positive lymph node status (P < 0.05), and have negatively correlated with the expression of MMP-2 and MMP-9. Overall survival was significantly shorter in patients with high tumour and stromal MMP-2 and MMP-9 expression, and tended to be shorter in patients with low ColIV expression.
Degradation of ColIV was closely related to increased MMP-2 and MMP-9 expression; MMP-9 have more important function than MMP-2 during the cancer development. Monitoring changes in the expression of ColIV, MMP-2, and MMP-9 may be a useful technique for assessing prognoses in OTSCC patients.
Oral tongue squamous cell carcinoma (OTSCC) is the most common malignancy diagnosed in the oral and maxillofacial regions, which is characterized by a high degree of local invasiveness and a high rate of metastasis to cervical lymph nodes. Notably, infiltration is a prerequisite and key step of cancer metastasis; and is an important factor in the prognosis of patients with oral cancer. Therefore, predictions of tumour infiltration and metastasis, and prognosis based on clinical parameters are of great clinical importance.
A key step in OTSCC infiltration and metastasis is the degradation of the basement membrane (BM) between the epithelium and lamina propria, around cancer nests, and surrounding vascular structures[3–5]. Type IV collagen (ColIV) is the most important scaffold for the BM proteins, and helps maintain continuity and integrity of the BM. Tongue squamous cell carcinoma is prone to infiltration, during which ColIV in and around epithelial, vascular and tumour BM is often damaged, thus compromising its ability to limit the tumour invasion and metastasis[7–9].
High levels of proteases and breaching of BM are key stages of cancer invasion. High levels of proteases facilitate degradation of BM and extracellular matrix (ECM), thus providing channels that allow tumour cells to migrate and metastasize the vascular and lymphatic systems. Furthermore, the invasiveness is associated with the ability of these proteases to degrade the BM.
The matrix metalloproteinase (MMP)-2 and MMP-9 are gelatinases, also called type IVcollagenases. They mainly degrade ColIV, the main component of BM and ECM; they also play a role in neovascularization. Various matrix metalloproteinases (MMPs) are secreted during the growth, invasion, metastasis, and angiogenesis of tumours, and affect the surrounding microenvironment, causing dynamic changes. Because ColIV is widely distributed in tongue tissue, its physiological and pathological significance in OTSCC has gradually attracted much attention.
Therefore, research on the MMPs that mediate invasion and metastasis of tongue cancer and the distribution and morphology of ColIV in and around epithelial and tumour BM is very necessary. In our present study, we aimed to investigate the expression of MMP-2, MMP-9 and ColIV, and the changes in the morphology of ColIV during tongue cancer development and their relationship with the stage and differentiation of OTSCC in order to determine if these results can be used to assess the prognosis in OTSCC patients.
Materials and methods
We collected 48 tissue samples from OTSCC patients diagnosed and treated at the Harbin Medical University Stomatological Hospital, Harbin, Heilongjiang, China, from the year 2000 to 2005. All specimens were obtained in accordance with the applicable ethical and legal standards. All patients underwent potentially curative surgery without preoperative therapy. The clinical and pathological characteristics of these patients are summarized in Table1. Non-cancerous tissue samples (normal group and dysplastic oral mucosa group) were obtained from the tissue 2.0–2.5 cm away from the primary tumour, and graded its organization according with the tissue morphologically. After treatment, all the patients were followed up until death or for at least 60 months. All the patients were staged according to the 1997 UICC TNM Classification of Malignant Tumours.
Formalin-fixed paraffin-embedded samples were sectioned at 5-μm thickness and stained with H&E for tumour confirmation. Sections adjacent to the H&E staining were used for immunohistochemical staining.
Monoclonal antibodies against MMP-2 (MAB-0244), MMP-9 (MAB-0245), and ColIV (MAB-0025) were all purchased from MaiXin Biological Technology Corporation Ltd. (Fujian, China). The concentrations of the primary antibody were 1:20 for MMP-2, 1:30 for MMP-9, and 1:100 for ColIV. The antibody was diluted with an antibody diluent.
Immunohistochemical staining was performed by using the universal two-step method. Briefly, the sections were first deparaffinized with xylene and rehydrated in graded ethanol. Endogenous peroxidase activity was blocked by immersion of slides in 3% hydrogen peroxide. 1% bovine serum albumin (BSA) was applied for 15 min for blocking non-specific antigens. The mixtures were then incubated with the respective primary antibodies overnight in a humidified chamber maintained at 4°C. Subsequently, they were incubated with the corresponding secondary antibody (PV6002, Zhongshan Goldenbridge Biotechnology, Beijing, China) for 30 min at 37°C. The antibody reaction was visualized by using diaminobenzidine (DAB) chromogen (Zhongshan Goldenbridge Biotechnology). Then, all the slides were counterstained with haematoxylin. Sections incubated with immunoglobulins of the same species at the same final concentrations served as negative controls, and placental trophoblastic cells (MMP-2,-9) and bronchial epithelial cells (ColIV) were used as positive controls.
Evaluation of immunohistochemical results
All samples were reviewed by two independent investigators who were blinded to the clinical outcomes of the patients. Image Pro Plus 6.0 (Media Cybernetics Inc.) was used to calculate the intensity of the detected molecules. Three microscopic fields in tumour tissues (original magnification 400×) were randomly selected and the integral optical density (iOD) of MMP-2, MMP-9 and ColIV was calculated by image, which was considered as the expression level of positive-staining. Higher iOD values represented higher antigen expression, and vice versa. All iOD values were divided into four quartiles as follows: 0–25%, negative expression; 25–50%, weak expression; 50–75%, moderate expression; and 75–100%, strong expression. For statistical analysis, the patients were classified into two groups: ‘low expression’ included those with negative or weak expression and ‘high expression’ included those with moderate or strong expression.
Statistical analyses were performed with SPSS software version 18.0 (SPSS Inc., Chicago, IL). The expression of MMP-2, MMP-9 and ColIV in normal oral mucosa, dysplastic oral mucosa and OTSCC tissues were expressed as the mean ± standard deviation. The association between the clinical parameters and immunohistochemical results was analyzed with the chi-square or Fisher’s exact test (if N < 5). Survival analysis was performed using Kaplan–Meier survival curves and the log-rank test. Spearman’s rank correlation coefficient test was applied for examining the correlations among the expressions of MMP-2, MMP-9 and ColIV. P-values < 0.05 were regarded to be statistically significant.
The immunohistologic expressions of MMP-2, MMP-9 and ColIV in normal oral mucosa group, dysplastic oral mucosa group and OTSCC tissues group are shown in Figure1.
The expression of MMP-2, MMP-9 and ColIV in normal oral mucosa group
Positive expression of MMP-2 and MMP-9 was mainly observed in the cytoplasm of stromal cells and proliferating epithelial cells as brownish granules under 400×. Positive staining was also noted in fibroblasts, microvascular endothelial cell cytoplasm. The positive-staining cells were flaky, spotty, or scattered. The expression of MMP-2 and MMP-9 in normal tongue mucosa epithelium was negative or weak positive (MMP-2: iOD 66.40 ± 24.20, Figure1A; MMP-9: iOD 88.05 ± 23.85, Figure1B). ColIV in the normal tongue mucosa, adjacent to basal cells, was observed as a continuous linear structure (ColIV: iOD 406.87 ± 62.95, Figure. 1C, Additional file1: Figure S1 A). Further, the surrounding blood vessels also tested positive for ColIV, showing a similar linear structure.
The expression of MMP-2, MMP-9 and ColIV in dysplastic oral mucosa group
In dysplastic oral mucosa group, the expression of MMP-2 in the basal cell layer was increased compared to normal tissue (MMP-2: iOD 134.69 ± 37.08, Figure1D). The basal cell layer showed significantly increased MMP-9 immunoreactivity, which was stronger than MMP-2 expression (MMP-9: iOD 307.13 ± 93.22, Figure1E). The expression of ColIV in the BM was not continuous linear or fragmented (ColIV: iOD 247.83 ± 42.30, Figure1F, Additional file1: Figure S1 B).
The expression of MMP-2, MMP-9 and ColIV in OTSCC tissue group
In the OTSCC tissues, MMP-2 expression was mainly observed in the stromal cells surrounding the epithelial nests of carcinoma (MMP-2: iOD 357.79 ± 116.78; Figure1G). In some well-differentiated nests of carcinomas, we found keratinization was distinct and the cancer cells were arranged sparsely. The expression of MMP-2 was also negative or weak positive (Figure1J).
The characteristic distribution pattern of MMP-9 showed a diffuse expression in tumour and stromal cells (MMP-9: iOD 791.31 ± 260.52; Figure1H). Moreover, MMP-9 positive cells were accumulated around the blood vessels (Figure1K). Thus, ColIV deposited surrounding cancer nests and formed membrane-like structures in tumour tissue. However, membrane-like structure fragmented, collapsed or even completely disappeared in most cases (ColIV: iOD 151.92 ± 38.17, Figure1I, Additional file1: Figure S1 C). Complete membrane-like structure could be observed only in small cases, but it became thick and sparse (Figure1L).
Association between MMP-2, MMP-9 and ColIV expression and clinic-pathological characteristics of tongue cancer
As shown in Table2, tumour MMP-2 expression was only detected in 14 of 48 specimens (low expression in 57% and high expression in 43%). However, for stromal MMP-2 expression, low positivity was noted in 40% of cases, whereas 60% showed high positivity. The presence of tumour MMP-2 expression was associated with differentiation and clinical stage. However, high stromal MMP-2 expression was only associated with positive lymph node status (P < 0.01).
Some level of MMP-9 expression was detected in the cytoplasm of the majority of the samples; 69% (33 of 48) of the cases showed high tumour MMP-9 expression (moderate or strong), while only 4 of 48 cases (8%) tested negative for MMP-9 expression. In all the specimens, stromal MMP-9 expression was detected, with 81% showing high expression. High expression of tumour and stromal MMP-9 were significantly associated with positive lymph node status (P < 0.01).
High ColIV expression was observed in 73% (35 of 48) of the samples. Col IV expression was associated with positive lymph node status (P < 0.05), and Spearman’s analysis revealed that the expressions of MMP-2 and MMP-9 were negatively correlated with ColIV expression (P < 0.01 and P < 0.001,respectively; Table3).
Correlation of MMP-2, MMP-9 and ColIV expression with patient survival by univariate analysis
Univariate analysis showed a statistically significant negative correlation between MMP-2 expression in the tumour cells and overall survival (Figure2A–B), i.e. patients with high MMP-2 expression had a shorter survival than patients with low MMP-2 expression. The same result was observed for a subgroup of patients with MMP-9 positive (P < 0.001) (Figure2C–D). In contrast, the relationship between overall survival and ColIV expression was inverse (P < 0.01) (Figure2E), i.e. patients with low ColIV expression had a shorter survival than did patients with high ColIV expression.
The distribution of ColIV in the BM of normal tongue mucosa is compatible with its corresponding functions. When pathological stimulating factors act on tongue mucosa, ColIV attached to the BM can effectively prevent harmful substances from penetrating the BM to the lamina propria[19–21]. Our present study shows, ColIV gradually reduced, was fragmented, collapsed, or even dissolved completely, thus providing channels for cancer cells to invade the lamina propria. ColIV also formed membrane-like structures in tumour tissue, but it became thick and sparse. In well-differentiated carcinomas, we observed that the thick and sparse ColIV around the cancer nests. In moderately and poorly differentiated tumours, the ColIV was destructed around cancer nests. The BM around the cancer nests can restrict tumour invasion and metastasis. So we believe that the well-differentiated tumours may have low malignant potential and weak invasiveness, while, the moderately and poorly differentiated carcinomas have high malignant potential and strong invasiveness. As a result, the massive dissolution of collagen fibers accelerates malignant progression of tumours. In this study, statistical analyses of ColIV showed that changes in their morphological were correlated with progression and differentiation of OTSCC, and with the prognosis of the patients. These results were consistent with Krecicki's findings.
It is recognized that carcinomatous invasion is regulated not only by intrinsic genetic changes in cancer cells as the ‘initiators’ of carcinogenesis but also by stromal cell that act as ‘promoters’[22, 23]. Interaction or synergy between tumour cells and stromal cells in the surrounding microenvironment (particularly, between tumour cells and stromal fibroblasts[24–26] and/or monocytes/macrophages[27, 28]) can promote tumour spread. This study showed that high MMP expression was found not only in tumour cells but also in stromal cells such as macrophages and vascular endothelial cells. As tumours progress, stromal cells secrete MMPs that can degrade BM and ECM; they can also facilitate tumour spread via interaction with tumour cells. Therefore, stromal cells’ role in tumour progression is of equal importance to that of tumour cells. We also found that patients with high MMP expression in the stromal cells tended to have poorer survival, as high MMP expression is closely tied to lymphatic metastasis. These findings are consistent with the previous studies[29–32]. High MMP-2 or MMP-9 expression in tumour or stromal cells might serve as prognostic predictors. Research on interaction between tumour cells and stromal cells aids further understanding of OTSCC invasiveness from aspects besides genetic mutation.
Our study also showed that expression of MMP-2 and MMP-9 are differentiated among tumours. As tumours progressed, MMP-9 expression increased in tumour epithelium and stroma, while the changes in MMP-2 expression in tumour cells was not as obvious as MMP-9. Double staining of the OTSCC indicated a co-localization of MMP-9 and PCNA (see Additional file1: Figure S2); correlation analysis showed MMP-9 expression to be positively correlated with that of PCNA (see Additional file2: Table S1). In other words, expression of MMP-9 protein was significantly increased in tongue cancer cells with strong proliferative ability, although such correlation was not significant for MMP-2. In blood vessels with high MMP-9 expression, ColIV in vascular basement membranes showed certain defects, or the BM became thin. Blood vessels without MMP-9 accumulation had no obvious changes in BM structure. Therefore, the MMP-9 expression may be closely related to proliferation, invasion and metastasis of tumour cells, and even to tumour angiogenesis. Yasumitsu et al. determined gelatinase activity in human schwannoma YST-3 cell lines using zymography, and found that MMP-9 activity in degrading collagen was about 25 times that of MMP−2. Previous studies suggested that MMP-9 expression were closely related to tumour angiogenesis than MMP-2[34, 35].
Obviously, tumour cells and stromal cells can expression high MMP levels, which are closely related to poor prognosis. In exploring ColIV expression, we also found that tumour expressions of MMP-2 and MMP-9 showed certain variations. The MMP-9 expression may be closely related to proliferation, invasion, and metastasis of tumour cells, and even to tumour angiogenesis. This may be related to the activity of MMP-9; however, its specific mechanism of action merits further research. In addition, which specific stromal cell (e.g. macrophages, fibroblasts, etc.) and which cell subtype (e.g. M1 and M2 macrophages) interact with tumour cells also remains unknown. Nevertheless, clinical application of agents that may inhibit MMP-9 secretion by stromal cells may be a key to achieving clinical control of invasion and metastasis of oral tumours.
Regezi JA, Sciubba JJ, Jordan RCK: Oral pathology : clinical pathologic correlations. 2008, St. Louis, Mo: Saunders/Elsevier
Byers RM, El-Naggar AK, Lee YY, Rao B, Fornage B, Terry NH, Sample D, Hankins P, Smith TL, Wolf PJ: Can we detect or predict the presence of occult nodal metastases in patients with squamous carcinoma of the oral tongue?. Head Neck. 1998, 20: 138-144. 10.1002/(SICI)1097-0347(199803)20:2<138::AID-HED7>3.0.CO;2-3.
Garamszegi N, Garamszegi SP, Samavarchi-Tehrani P, Walford E, Schneiderbauer MM, Wrana JL, Scully SP: Extracellular matrix-induced transforming growth factor-beta receptor signaling dynamics. Oncogene. 2010, 29: 2368-2380. 10.1038/onc.2009.514.
Gustafsson E, Fassler R: Insights into extracellular matrix functions from mutant mouse models. Exp Cell Res. 2000, 261: 52-68. 10.1006/excr.2000.5042.
Egeblad M, Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002, 2: 161-174. 10.1038/nrc745.
Kadler KE, Hill A, Canty-Laird EG: Collagen fibrillogenesis: fibronectin, integrins, and minor collagens as organizers and nucleators. Current Opin Cell Biol. 2008, 20: 495-501. 10.1016/j.ceb.2008.06.008.
Ushiki T: Collagen fibers, reticular fibers and elastic fibers. A comprehensive understanding from a morphological viewpoint. Arch Histol Cytol. 2002, 65: 109-126. 10.1679/aohc.65.109.
Souza LF, Souza VF, Silva LD, Santos JN, Reis SR: Expression of basement membrane laminin in oral squamous cell carcinomas. Braz J Otorhinolaryngol. 2007, 73: 768-774.
Liu G, Li J, Li Z, Yan J: [Measurement of content of collagen type IV and laminin in tissue of oral squamous cell carcinoma and its clinical significance]. China J Stomatol Res. 2000, 18: 98-100.
Rowe RG, Weiss SJ: Breaching the basement membrane: who, when and how?. Trends Cell Biol. 2008, 18: 560-574. 10.1016/j.tcb.2008.08.007.
Duffy MJ, McGowan PM, Gallagher WM: Cancer invasion and metastasis: changing views. J Pathol. 2008, 214: 283-293. 10.1002/path.2282.
Kurahara S, Shinohara M, Ikebe T, Nakamura S, Beppu M, Hiraki A, Takeuchi H, Shirasuna K: Expression of MMPS, MT-MMP, and TIMPs in squamous cell carcinoma of the oral cavity: correlations with tumour invasion and metastasis. Head Neck. 1999, 21: 627-638. 10.1002/(SICI)1097-0347(199910)21:7<627::AID-HED7>3.0.CO;2-2.
Stamenkovic I: Matrix metalloproteinases in tumour invasion and metastasis. Semin Cancer Biol. 2000, 10: 415-433. 10.1006/scbi.2000.0379.
Liotta LA, Steeg PS, Stetler-Stevenson WG: Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell. 1991, 64: 327-336. 10.1016/0092-8674(91)90642-C.
Kessenbrock K, Plaks V, Werb Z: Matrix metalloproteinases: regulators of the tumour microenvironment. Cell. 2010, 141: 52-67. 10.1016/j.cell.2010.03.015.
Zhang Z, Pan J, Li L, Wang Z, Xiao W, Li N: Survey of risk factors contributed to lymphatic metastasis in patients with oral tongue cancer by immunohistochemistry. J Oral Pathol Med. 2011, 40: 127-134. 10.1111/j.1600-0714.2010.00953.x.
Sobin LH, Fleming ID: TNM Classification of Malignant Tumours, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer. 1997, 80: 1803-1804. 10.1002/(SICI)1097-0142(19971101)80:9<1803::AID-CNCR16>3.0.CO;2-9.
Rhodes A, Jasani B, Balaton AJ, Barnes DM, Anderson E, Bobrow LG, Miller KD: Study of interlaboratory reliability and reproducibility of estrogen and progesterone receptor assays in Europe. Documentation of poor reliability and identification of insufficient microwave antigen retrieval time as a major contributory element of unreliable assays. Am J Clin Pathol. 2001, 115: 44-58. 10.1309/H905-HYC1-6UQQ-981P.
Krecicki T, Zalesska-Krecicka M, Jelen M, Szkudlarek T, Horobiowska M: Expression of type IV collagen and matrix metalloproteinase-2 (type IV collagenase) in relation to nodal status in laryngeal cancer. Clin Otolaryngol Allied Sci. 2001, 26: 469-472. 10.1046/j.0307-7772.2001.00503.x.
Santos-Garcia A, Abad-Hernandez MM, Fonseca-Sanchez E, Julian-Gonzalez R, Galindo-Villardon P, Cruz-Hernandez JJ, Bullon-Sopelana A: E-cadherin, laminin and collagen IV expression in the evolution from dysplasia to oral squamous cell carcinoma. Med Oral Patol Oral Cir Bucal. 2006, 11: E100-E105.
Bar JK, Grelewski P, Popiela A, Noga L, Rabczynski J: Type IV collagen and CD44v6 expression in benign, malignant primary and metastatic ovarian tumours: correlation with Ki-67 and p53 immunoreactivity. Gynecol Oncol. 2004, 95: 23-31. 10.1016/j.ygyno.2004.06.046.
Ingber DE: Can cancer be reversed by engineering the tumour microenvironment?. Semin Cancer Biol. 2008, 18: 356-364. 10.1016/j.semcancer.2008.03.016.
Albini A, Sporn MB: The tumour microenvironment as a target for chemoprevention. Nat Rev Cancer. 2007, 7: 139-147.
Silzle T, Randolph GJ, Kreutz M, Kunz-Schughart LA: The fibroblast: sentinel cell and local immune modulator in tumour tissue. Int J Cancer. 2004, 108: 173-180. 10.1002/ijc.11542.
Kalluri R, Zeisberg M: Fibroblasts in cancer. Nat Rev Cancer. 2006, 6: 392-401. 10.1038/nrc1877.
Shimoda M, Mellody KT, Orimo A: Carcinoma-associated fibroblasts are a rate-limiting determinant for tumour progression. Semin Cell Dev Biol. 2010, 21: 19-25. 10.1016/j.semcdb.2009.10.002.
Qian BZ, Pollard JW: Macrophage diversity enhances tumour progression and metastasis. Cell. 2010, 141: 39-51. 10.1016/j.cell.2010.03.014.
Mantovani A: La mala educacion of tumour-associated macrophages: Diverse pathways and new players. Cancer Cell. 2010, 17: 111-112. 10.1016/j.ccr.2010.01.019.
Sobral LM, Bufalino A, Lopes MA, Graner E, Salo T, Coletta RD: Myofibroblasts in the stroma of oral cancer promote tumourigenesis via secretion of activin A. Oral Oncol. 2011, 47: 840-846. 10.1016/j.oraloncology.2011.06.011.
Kamat AA, Fletcher M, Gruman LM, Mueller P, Lopez A, Landen CN, Han L, Gershenson DM, Sood AK: The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer. Clin Cancer Res. 2006, 12: 1707-1714. 10.1158/1078-0432.CCR-05-2338.
Ranogajec I, Jakic-Razumovic J, Puzovic V, Gabrilovac J: Prognostic value of matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9) and aminopeptidase N/CD13 in breast cancer patients. Med Oncol. 2011, 29: 561-569.
Zhou CX, Gao Y, Johnson NW, Gao J: Immunoexpression of matrix metalloproteinase-2 and matrix metalloproteinase-9 in the metastasis of squamous cell carcinoma of the human tongue. Aust Dent J. 2010, 55: 385-389. 10.1111/j.1834-7819.2010.01258.x.
Yasumitsu H, Miyazaki K, Umenishi F, Koshikawa N, Umeda M: Comparison of extracellular matrix-degrading activities between 64-kDa and 90-kDa gelatinases purified in inhibitor-free forms from human schwannoma cells. J Biochem. 1992, 111: 74-80.
Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, Hanahan D: Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol. 2000, 2: 737-744. 10.1038/35036374.
Giraudo E, Inoue M, Hanahan D: An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest. 2004, 114: 623-633.
This work was supported by grants from the National Natural Science Foundation of China (305400083).
The authors declare that they have no competing interests.
HXF and HXL conceived and designed the experiments. HXF and HXL performed the experiments and analyzed the data. ZXZG contributed to the acquisition of the data, DC has made substantial contribution to collected tissue samples, and HXF, HXL, and JHZ wrote the manuscript. All authors have read and approved the final manuscript.
Hai-Xia Fan, Hai-Xia Li contributed equally to this work.